U.S. Intravenous Iron Drugs Market Size & Outlook
U.S. intravenous iron drugs market, 2018-2030 (US$M)
Related Markets
U.S. intravenous iron drugs market highlights
- The U.S. intravenous iron drugs market generated a revenue of USD 1,446.4 million in 2023 and is expected to reach USD 2,393.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, ferric carboxymaltose was the largest revenue generating product in 2023.
- Iron Sucrose is the most lucrative product segment registering the fastest growth during the forecast period.
Intravenous iron drugs market data book summary
| Market revenue in 2023 | USD 1,446.4 million |
| Market revenue in 2030 | USD 2,393.2 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Ferric carboxymaltose |
| Fastest growing segment | Iron Sucrose |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.8% of the global intravenous iron drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. intravenous iron drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 213.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 47.44% in 2023. Horizon Databook has segmented the U.S. intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in the number of anemia cases is driving the market growth of IV iron drugs. In the U.S., according to the National Heart, Lung, and Blood Institute, over 3 million people are affected with anemia in the country. Based on CDC data, around 2.8 million people visited physician offices and around 890,000 people visited emergency departments with anemia as a part of primary diagnosis.
Rise in number of cancer cases in the U.S. has also impelled the number of IDA cases. With chemotherapy and radiation therapy, the chances of IDA increase, thereby leading to increased demand for IV iron drugs.
On the basis of a study published by American Academy of Family Physicians, 9% of patients above 65 years of age with IDA, when evaluated, confirmed that they have gastrointestinal cancer. CKD is also another significant cause of anemia. As per NCBI statistics, the prevalence of anemia in CKD patients was 15.4% in the U.S.
Reasons to subscribe to U.S. intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into U.S. intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. intravenous iron drugs market size, by product, 2018-2030 (US$M)
U.S. Intravenous Iron Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
